What is the recommended protocol for subcutaneous bremelanotide administration in a premenopausal adult woman with hypoactive sexual desire disorder, including eligibility criteria, dosing, injection technique, site rotation, monitoring, and contraindications?

Bremelanotide Subcutaneous Injection Protocol for Premenopausal Women with HSDD

Administer bremelanotide 1.75 mg subcutaneously to the abdomen or thigh at least 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than 8 doses per month. 1

Patient Eligibility Criteria

Inclusion Requirements:

• Premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
• Low sexual desire causing marked distress or interpersonal difficulty
• Symptoms NOT attributable to:
  • Co-existing medical or psychiatric conditions
  • Relationship problems
  • Effects of medications or substances 1

Absolute Contraindications:

• Uncontrolled hypertension
• Known cardiovascular disease 1

Relative Contraindications/High Caution:

• Patients at high cardiovascular risk (bremelanotide causes transient BP increases and HR decreases after each dose) 1, 2
• Darker skin tones (higher risk of focal hyperpigmentation, particularly with frequent dosing) 1

Dosing Protocol

Standard Dose:

• 1.75 mg/0.3 mL subcutaneous injection 1
• Administer at least 45 minutes before anticipated sexual activity 1, 3

Frequency Restrictions:

• Maximum: 1 dose per 24 hours 1
• Maximum: 8 doses per month 1
• Critical warning: More frequent dosing leads to more pronounced blood pressure increases 1

Trial Period:

• Discontinue if no improvement after 8 weeks of use 4

Injection Technique

Site Selection:

• Abdomen (avoid 2-inch radius around navel) OR anterior thigh 1
• Rotate injection sites with each dose 1
• Avoid areas that are irritated, sore, bruised, red, hard, or scarred 1

Preparation:

• Wash hands with soap and water 1
• Clean injection site with alcohol wipe and allow to air dry 1
• Do not inject through clothing 1

Administration Using Autoinjector:

1. Remove clear cap from purple tip (use immediately after cap removal) 1
2. Place purple tip flat against center of cleaned injection site 1
3. Press down firmly and hold—you will hear first click immediately (injection started) 1
4. After ~2 seconds, you will hear second click 1
5. Continue pressing firmly for 5 seconds after the second click to ensure complete delivery 1
6. Verify view window is purple with small gray tip showing (confirms complete dose) 1
7. Lift autoinjector straight off skin 1

Post-Injection:

• Apply pressure with cotton ball/gauze if bleeding occurs 1
• Apply adhesive bandage if needed 1
• Do NOT rub injection site 1
• Dispose of autoinjector immediately in FDA-cleared sharps container 1

Monitoring Requirements

Cardiovascular Monitoring:

• Assess cardiovascular risk before initiating therapy 1
• Ensure blood pressure is well-controlled before starting 1
• Monitor blood pressure periodically during treatment 1
• Counsel patients that BP increases and HR decreases occur after each dose, typically resolving within 12 hours 1

Skin Monitoring:

• Examine for focal hyperpigmentation at each visit, particularly on face, gingiva, and breasts 1
• Risk increases with daily dosing (occurred in >33% with 16 consecutive daily doses) 2
• Important: Pigmentary changes may not resolve completely after discontinuation 1
• Consider discontinuation if hyperpigmentation develops 1

Symptom Assessment:

• Reassess HSDD symptoms after 8 weeks of treatment 4
• Discontinue if no benefit after 8-week trial 4

Management of Common Adverse Effects

Nausea (40% incidence):

• Most common with first injection, may occur intermittently 1, 2
• Typically lasts 2 hours but can persist longer 1
• Usually improves with second dose 1
• Consider prophylactic anti-emetic therapy if persistent 1
• Discontinue if severe or persistent despite anti-emetics 1
• Nausea is the most common reason for discontinuation 2

Other Common Adverse Effects:

• Flushing (20.3%) 2
• Headache (11.3%) 2
• Injection site reactions (5.4%) 2

Most adverse events are mild to moderate in severity 2.

Drug Interactions

Significant Interactions:

• Avoid concomitant use with oral naltrexone (for alcohol/opioid addiction treatment)—bremelanotide significantly decreases naltrexone systemic exposure 1
• May slow gastric emptying and impact absorption of oral medications 1
• Lowers plasma concentrations of indomethacin 2

No Clinically Significant Interaction:

• Ethanol 4

Special Populations

Pregnancy:

• Advise patients to use effective contraception during treatment 1
• Discontinue immediately if pregnancy suspected 1
• Pregnancy registry available: 800-972-5220 1

Breastfeeding:

• Unknown if bremelanotide passes into breast milk 1
• Discuss risks/benefits with patient 1

Patient Counseling Points

• Emphasize strict adherence to dosing frequency limits (24-hour minimum between doses, 8 doses maximum per month) 1
• Warn about transient cardiovascular effects that resolve within 12 hours 1
• Discuss risk of permanent skin darkening, especially in darker-skinned individuals 1
• Set realistic expectations: clinical benefit is modest despite statistical significance in trials 4, 5
• Provide sharps disposal container and education 1

Clinical Efficacy Context

The phase 3 RECONNECT trials demonstrated statistically significant improvements in FSFI-desire domain scores (integrated studies: 0.35, P<.001) and reductions in distress (FSDS-DAO item 13: -0.33, P<.001) compared to placebo 6. However, the absolute clinical benefit is modest 4, 7, and 70% of bremelanotide patients continued to open-label phase versus 87% on placebo, suggesting tolerability concerns 2.